NCT00782600 - Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Rheumatoid Arthritis

Interventions

DRUG

suspension IR

50 mg IR suspension once daily for one day

DRUG

CR 1

50 mg shorter release CR once daily for one day

DRUG

CR 2

50 mg medium release CR once daily for one day

DRUG

CR 3

longer release SR formulation once daily for one day

Trial Locations (1)

Pfizer Investigational Site, New Haven